Armata Pharmaceuticals Q3 EPS Reduced by HC Wainwright

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Analysts at HC Wainwright lowered their Q3 2026 earnings estimates for Armata Pharmaceuticals in a note issued to investors on Thursday, August 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.57) per share for the quarter, down from their prior forecast of ($0.53). The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is $0.50 per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at ($2.04) EPS.

Separately, Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a research note on Monday, May 18th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Armata Pharmaceuticals Stock Performance

NYSEAMERICAN:ARMP opened at $4.48 on Monday. The firm has a 50-day simple moving average of $5.52 and a 200-day simple moving average of $8.11. Armata Pharmaceuticals has a one year low of $2.40 and a one year high of $16.34. The firm has a market cap of $164.46 million, a P/E ratio of -0.59 and a beta of 1.30.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.17. The company had revenue of $2.51 million for the quarter, compared to analysts’ expectations of $0.40 million. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%.

Institutional Investors Weigh In On Armata Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ARMP. Madison Asset Management LLC purchased a new position in Armata Pharmaceuticals in the first quarter valued at about $21,583,000. 683 Capital Management LLC bought a new position in Armata Pharmaceuticals in the fourth quarter worth about $878,000. Geode Capital Management LLC lifted its position in shares of Armata Pharmaceuticals by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after buying an additional 5,342 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Armata Pharmaceuticals by 65.9% during the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock valued at $430,000 after buying an additional 27,200 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after buying an additional 10,500 shares during the last quarter. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.